Literature DB >> 2550059

Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line.

D M Sullivan1, M D Latham, T C Rowe, W E Ross.   

Abstract

The cytotoxicity and DNA damage induced by the epipodophyllotoxins and several intercalating agents appear to be mediated by DNA topoisomerase II. We have purified topoisomerase II to homogeneity both from an epipodophyllotoxin-resistant Chinese hamster ovary cell line, VpmR-5, and from the wild-type parental cell line. Immunoblots demonstrate similar topoisomerase II content in these two cell lines. The purified enzymes are dissimilar in that DNA cleavage by VpmR-5 topoisomerase II is not stimulated by VP-16 or m-AMSA. Furthermore, the VpmR-5 enzyme is unstable at 37 degrees C. Thus, the drug resistance of VpmR-5 cells appears to result from the presence of an altered topoisomerase II in these cells. Purified topoisomerase II from VPMR-5 and wild-type cells has the same monomeric molecular mass as well as equivalent catalytic activity with respect to decatenation of kinetoplast DNA. Etoposide (VP-16) inhibits the activity of both enzymes. Noncovalent DNA-enzyme complex formation, assayed by nitrocellulose filter binding, is also similar, as is protection from salt dissociation of this complex by ATP and VP-16. The data suggest a model in which the drug-resistant cell line, VpmR-5, has religation activity which is less affected by drug than that of the wild-type cells. Drug effect on DNA religation and catalytic activity are dissociated mechanistically. In addition, under certain circumstances, the "cleavable complex" observed following denaturation of a drug-stabilized DNA-enzyme complex may not adequately reflect the nature of the antecedent lesion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550059     DOI: 10.1021/bi00439a051

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  23 in total

1.  Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids.

Authors:  B S Glisson; A M Killary; P Merta; W E Ross; J Siciliano; M J Siciliano
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene.

Authors:  T Asano; T An; J Mayes; L A Zwelling; E S Kleinerman
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

Review 3.  Altered DNA topoisomerase II in multidrug resistance.

Authors:  W T Beck; M K Danks; J S Wolverton; B Granzen; M Chen; C A Schmidt; B Y Bugg; E Friche; D P Suttle
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II.

Authors:  D A Burden; L J Goldsmith; D M Sullivan
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

Review 5.  Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.

Authors:  N Osheroff; A H Corbett; S H Elsea; M Westergaard
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Chromosome recombination and defective genome segregation induced in Chinese hamster cells by the topoisomerase II inhibitor VM-26.

Authors:  M Charron; R Hancock
Journal:  Chromosoma       Date:  1991-02       Impact factor: 4.316

7.  Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.

Authors:  Ryan P Bender; Michael J Jablonksy; Mohammad Shadid; Ian Romaine; Norma Dunlap; Clemens Anklin; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2008-03-21       Impact factor: 3.162

8.  Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Authors:  Joel G Turner; Douglas C Marchion; Jana L Dawson; Michael F Emmons; Lori A Hazlehurst; Peter Washausen; Daniel M Sullivan
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

9.  Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

Authors:  B Y Bugg; M K Danks; W T Beck; D P Suttle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

10.  Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.

Authors:  C H Freudenreich; K N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.